Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers
Conclusion In mBTC, the addition of bevacizumab to GEMOX increased the progression-free survival and was associated with manageable toxicity. These data pave the way for further evaluation of antiangiogenic agents in mBTC.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Drugs & Pharmacology | Eloxatin | Investigational New Drugs | Toxicology